CEBPA and metabolic dysfunction-associated steatohepatitis: Preclinical efficacy of MTL-CEBPA was first demonstrated in rat liver diseases, treatment with MTL-CEBPA resulted in the increase of CEBPA expression in the liver and this promotes disease reversal of several models including the DEN-induced cirrhotic hepatocellular carcinoma (HCC), carbon-tetrachloride-induced fibrosis and the methionine and choline-deficient diet-induced non-alcoholic steatohepatitis [53].